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HAART as a treatment regimen for HIV-infected individ-
uals at a Veterans Affairs Medical Center. STUDY DE-
SIGN: This was a retrospective database study covering
five US government fiscal years (1994 through 1998).
During that time frame, protease inhibitors were intro-
duced, allowing the use of potent combination drug ther-
apy known as highly-active antiretroviral therapy
(HAART). METHODS: Survival methods were used to
analyze differences in total costs of care and survival be-
tween two cohorts treated when HAART was not avail-
able and when HAART was available. Survival was mea-
sured in days. Health care costs were available for
hospitalizations, clinic visits, outpatient medications, and
laboratory procedures. A sensitivity analysis was per-
formed to determine the impact of estimates for the costs
of clinic visits of varying lengths. RESULTS: Statistically
significant improvements in survival and reductions in
costs were observed for the time period after HAART be-
came available. Mean survival increased from 589 days
before the availability of HAART to 702 days after
HAART became available (P  0.001). Median annual
costs of care decreased from $29,477 to $16,219 (P 
0.001). CONCLUSIONS: The availability of potent, yet
expensive, antiretroviral medications for the treatment of
HIV-infected individuals at the Denver VAMC has re-
sulted in improved survival and lower overall medical
care costs.
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AN ANALYSIS OF THE IMPACT OF MEDICATION 
NON-ADHERENCE AND TYPE OF MEDICATION 
ON OUTCOME DOMAINS USING THE SCAP 
HEALTH QUESTIONNAIRE
Russo P, Dirani R
The MEDSTAT Group, Inc., Washington, DC, USA
OBJECTIVE: To model the effects of medication non-
adherence and type of medication on health status, func-
tioning, and quality of life outcomes for persons with
schizophrenia enrolled in the US Schizophrenia Care and
Assessment Program (SCAP). METHODS: Data were
obtained from SCAP study participants who completed
the baseline and the 6-month assessments and who were
using antipsychotic medications (n  530). Baseline char-
acteristics and type of medication were used to predict 6-
month outcomes as measured by the SCAP Health Ques-
tionnaire (SCAPHQ). Adherence at baseline and at six
months reflected the 4-week period prior to each assess-
ment. Health status (health score), functioning (social
and daily activity), and quality of life (general life satis-
faction) were modeled using ordinary least squares. RE-
SULTS: No family history, undifferentiated type, private
health insurance, and Medicare only were predictive of
higher health scores. Being married and non-adherence at
six months were predictive of lower health scores. Within
the functioning domain, a college education and better
health were predictors of higher social activities scores
while persons on CHAMPUS exhibited lower scores. Bet-
ter health, undifferentiated type, and summer birth were
predictive of higher life satisfaction. Cohort (recently
hospitalized) and medication non-adherence (at baseline
and at 6 months) exhibited a negative impact on life sat-
isfaction. CONCLUSIONS: These findings suggest that
prior period self-reported adherence may be predictive of
subsequent period outcomes in health status and quality
of life. Medication non-adherence is significantly associ-
ated with lower health status and lower life satisfaction
and exhibits a negative (though non-significant) impact
on functioning outcomes. Education and health status
are important determinants of functioning outcomes.
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Between 7/93 and 6/95, Medicare gradually extended
its maintenance immunosuppression medication (MIM)
coverage from 1 to its current 3 years. OBJECTIVES:
We hypothesized that lower income recipients would
be more non-compliant because of the high cost of
MIMs. We examined whether Medicare’s extension
benefited low-income recipients more. METHODS:
We matched median family income for each patient’s
ZIP code from the 1990 Census with clinical data on
first cadaveric renal transplants from the USRDS-dis-
tributed UNOS registry. We used Kaplan-Meier plots
and Cox Proportional Hazards Models to analyze the
differences in graft survival in the two chronological
cohorts (6,279 and 10,060 recipients before and after
the extended coverage, respectively) and two income
groups (above and below the upper quartile family in-
come of $33,277). RESULTS: When Medicare cov-
ered MIMs for 1 year, the high and lower income
groups had equivalent graft survival at 1 year. By 3
years post-transplant the lower income group had a
4.4% greater graft failure (P  0.001). Among 1 year
survivors, the lower income group eligible for only 1
year MIM coverage had a 5% greater graft failure at
the end of three years post-transplant (P  0.001).
The risk ratios from a multivariate Cox Proportional
Hazards model indicate that Medicare’s extended cov-
erage eliminated the entire differential graft loss asso-
ciated with lower incomes. Even in the next-to-highest
income quartile, the graft loss (RR  1.37, P  0.008)
and the benefits of extended coverage (RR  0.70,
P  0.035) were significant. CONCLUSION: We in-
fer that extended MIM coverage improved compliance
for all but the highest income recipients. This should
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be considered when prescription drug benefits are de-
signed.
DH3
PUBLIC REPORT SPURS HOSPITAL 
MORTALITY REDUCTION
Czerwinski AA, Horgan MM
Care Management Science Corporation, Philadelphia, PA, USA
OBJECTIVE: The State Hospital Association (SHA) in a
large Midwestern state annually publishes risk-adjusted
mortality rates on selected groups of patients, by hospi-
tal. For the third year in a row, the SHA reported a
higher than expected mortality rate for Non-Surgical
‘Heart’ cases at Memorial, and the Board of Directors
asked for an improvement plan. METHODS: We used
the CaduCIS risk assessment methodology to indepen-
dently validate the SHA’s findings, and conducted oppor-
tunity analyses to identify a specific sub-population which
seemed to be the major contributor to the mortality rate.
RESULTS: (1) Most of the “excess” mortality seemed to
occur in medically managed AMI patients. (2) While a
few physicians cared for high volumes of such patients, a
surprising number of physicians had very low volumes.
(3) Risk-adjusted outcomes for the low-volume physi-
cians were significantly worse than predicted. (4) A non-
cardiologist was the attending physician for fully 25% of
the medically managed patients. (5) A small percentage
(4%) of medically managed AMI cases were admitted to
the Neuro ICU rather than the Cardiac ICU—but the
mortality rate in that subgroup was 58%—11% of the
total deaths. (6) Thrombolytic therapy was administered
to only 1% of medically managed AMI patients. (7) Beta-
blockers were administered to only 58% of patients. Im-
provement strategies included retargeting educational
programs, providing ongoing feedback on mortality rates,
and modifying clinical protocols. CONCLUSIONS: (1)
For the three-month time period following the implemen-
tation of improvement strategies for medically managed
AMI patients, the mortality rate decreased from 19% to
8%. (2) No AMI patients were admitted to the Neuro
ICU. (3) The proportion of AMI admissions directly
managed by cardiologists increased to 84%. (4) The fre-
quency of beta-blocker administration improved to 82%.
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PROGRAM (SCAP): IMPACT OF CLINICAL AND 
FUNCTIONAL STATUS AND TYPE OF 
MEDICATION TREATMENT ON OUTPATIENT 
PSYCHIATRIC UTILIZATION
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OBJECTIVE: To examine the impact of demographics,
clinical/functional status, and type of medication on out-
patient utilization for persons enrolled in the US Schizo-
phrenia Care and Assessment Program (SCAP). METH-
ODS: Baseline data was used to predict 6-month
outpatient utilization (n  530). Psychotherapy (individ-
ual and group), clinic (medical services for specimen col-
lection), and total number of outpatient visits (psycho-
therapy, clinic, day treatment, rehabilitation) were examined.
Adherence at baseline and at six months reflected the 4-
week period prior to each assessment. Negative binomial
regression was used and predicted values obtained
through joint determination (SURE) of clinical/functional
status were used in the models. Standard errors were ad-
justed. RESULTS: Psychotherapy Visits: Persons using
second-generation medications exhibited more psycho-
therapy visits than their counterparts using first-genera-
tion agents and adherence at baseline only exhibited a
positive association. Clinic Visits: Non-whites exhibited
fewer visits and adherence at baseline only was associ-
ated with more visits. Total Outpatient Visits: 1) Persons
in better health exhibited more visits; 2) adherence at
baseline only was positively associated with more outpa-
tient visits; and 3) higher PANSSGP was positively associ-
ated with total visits while higher MADRS exhibited a
negative association. Season of birth and site of service
were significant in the models. CONCLUSIONS: Clinical/
functional status, medication regimen, and medication
non-adherence are significant determinants of psychiatric
service utilization. The presence of second-generation
medications, better health, and adherence to medications
is associated with greater involvement in psychotherapy,
which suggests the possibility that these factors may pro-
mote community functioning.
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Using input from consumers, clinical staff, and quality of
life experts, we developed a self-administered, health-
related quality of life instrument for individuals with
schizophrenia living in the community—the Schizophre-
nia Outcomes Assessment Project 51-item Health Status
Survey (SOAP-51). OBJECTIVE: To establish the con-
current and discriminatory validity of the SOAP-51
Health Status Survey. METHOD: We asked 1500 indi-
viduals with schizophrenia and their caregivers in 5 eth-
nically and geographically diverse states to complete the
SOAP-51; retention was 84.2%. For concurrent valida-
tion, consumers were asked to globally rate the impact of
their condition on each of SOAP-51’s 8 factors; Cron-
bach’s alpha was 0.711–0.881, test-retest reliability was
